GAFA
REGN icon

Garton & Associates Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Garton & Associates Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12
Closed -$9.29K – 573
2025
Q4 		$9.29K Buy
+12
New +$8.15K 0.01% 852

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Garton & Associates Financial Advisors's REGN Position: Q1 2026 in Review

Garton & Associates Financial Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 12 shares — an estimated $9.29K sold.

Garton & Associates Financial Advisors first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $9.29K in Q4 2025. 1,398 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Garton & Associates Financial Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Garton & Associates Financial Advisors sold 12 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $9.29K.
  • Garton & Associates Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Garton & Associates Financial Advisors's Regeneron Pharmaceuticals position peaked at $9.29K in Q4 2025.
  • 1,398 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Garton & Associates Financial Advisors's 13F filing for Q1 2026, filed 11 May 2026.